DYAZIDE
LOE ApproachingNDAORALCAPSULE
Approved
Dec 1965
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 15h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DYAZIDE is an oral capsule small-molecule drug approved in 1965 by GSK. The specific mechanism of action and indications are not publicly detailed in available data, but the product has maintained market presence for nearly 60 years. As a legacy NDA product, it represents a mature therapeutic asset in GSK's portfolio.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30/100), signaling a declining or maintenance-focused commercial team structure.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on DYAZIDE offers limited career growth opportunity given its approaching LOE and zero linked job postings. Roles are predominantly defensive, focused on market maintenance, generic transition management, and cost optimization rather than innovation or expansion.
Brand Manager (Maintenance)Field Sales Representative
Worked on DYAZIDE at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.